Hellman Jordan Management Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Hellman Jordan Management Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.54M	Buy	5,349 +708	+15%	+$216K	2.62%	16
2022 Q3	$1.34M	Sell	4,641 -2,011	-30%	-$579K	2.33%	17
2022 Q2	$1.87M	Buy	6,652 +1,786	+37%	+$478K	2.52%	9
2022 Q1	$1.27M	Sell	4,866 -2,921	-38%	-$693K	1.38%	25
2021 Q4	$1.71M	Sell	7,787 -3,074	-28%	-$598K	2.05%	18
2021 Q3	$1.97M	Buy	10,861 +3,346	+45%	+$653K	2.77%	9
2021 Q2	$1.51M	Buy	7,515 +11	+0.1%	+$2.3K	2.69%	8
2021 Q1	$1.61M	Buy	7,504 +6,580	+712%	+$1.45M	2.34%	11
2020 Q4	$218K	Buy	924 +70	+8%	+$16.1K	0.69%	18
2020 Q3	$232K	Buy	854 +18	+2%	+$4.97K	0.44%	17
2020 Q2	$243K	Sell	836 -6	-0.7%	-$1.63K	0.39%	19
2020 Q1	$200K	Buy	+842	New	+$193K	0.47%	20

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Hellman Jordan Management Company's VRTX Position: Q4 2022 in Review

Hellman Jordan Management Company increased its Vertex Pharmaceuticals (VRTX) stake by 15% in Q4 2022, buying an estimated $216K and bringing the position to 5,349 shares worth $1.54M. The position accounts for 2.62% of the portfolio, ranked #16.

Hellman Jordan Management Company first reported a position in VRTX in Q1 2020 and has held it in 12 quarters since. The position peaked at $1.97M in Q3 2021. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Hellman Jordan Management Company held 5,349 shares of Vertex Pharmaceuticals worth $1.54M as of Q4 2022.
Hellman Jordan Management Company bought 708 Vertex Pharmaceuticals shares in Q4 2022, an estimated $216K.
Vertex Pharmaceuticals made up 2.62% of Hellman Jordan Management Company's portfolio in Q4 2022, its #16 holding.
Hellman Jordan Management Company first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 12 quarters since.
Hellman Jordan Management Company's Vertex Pharmaceuticals position peaked at $1.97M in Q3 2021.
1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Hellman Jordan Management Company's 13F filing for Q4 2022, filed 20 Jan 2023.